# BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer

> **NCT00054314** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** ortataxel

## Key facts

- **NCT ID:** NCT00054314
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2003-04
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00054314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00054314, "BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00054314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*